These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29381145)

  • 1. A dataset of 200 structured product labels annotated for adverse drug reactions.
    Demner-Fushman D; Shooshan SE; Rodriguez L; Aronson AR; Lang F; Rogers W; Roberts K; Tonning J
    Sci Data; 2018 Jan; 5():180001. PubMed ID: 29381145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning-based identification and rule-based normalization of adverse drug reactions in drug labels.
    Tiftikci M; Özgür A; He Y; Hur J
    BMC Bioinformatics; 2019 Dec; 20(Suppl 21):707. PubMed ID: 31865904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mining FDA drug labels using an unsupervised learning technique--topic modeling.
    Bisgin H; Liu Z; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2011 Oct; 12 Suppl 10(Suppl 10):S11. PubMed ID: 22166012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information on adverse drug reactions-Proof of principle for a structured database that allows customization of drug information.
    Kusch MKP; Zien A; Hachenberg C; Haefeli WE; Seidling HM
    Int J Med Inform; 2020 Jan; 133():103970. PubMed ID: 31704490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Event extraction from Structured Product Labels using the Event-based Text-mining of Health Electronic Records (ETHER) system.
    Pandey A; Kreimeyer K; Foster M; Dang O; Ly T; Wang W; Forshee R; Botsis T
    Health Informatics J; 2019 Dec; 25(4):1232-1243. PubMed ID: 29359620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science.
    Fang H; Harris SC; Liu Z; Zhou G; Zhang G; Xu J; Rosario L; Howard PC; Tong W
    Drug Discov Today; 2016 Oct; 21(10):1566-1570. PubMed ID: 27319291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supervised signal detection for adverse drug reactions in medication dispensing data.
    Hoang T; Liu J; Roughead E; Pratt N; Li J
    Comput Methods Programs Biomed; 2018 Jul; 161():25-38. PubMed ID: 29852965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ontology-based literature mining and class effect analysis of adverse drug reactions associated with neuropathy-inducing drugs.
    Hur J; Özgür A; He Y
    J Biomed Semantics; 2018 Jun; 9(1):17. PubMed ID: 29880031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing Deep Learning for Detecting Adverse Drug Events in Structured and Unstructured Regulatory Drug Data Sets.
    Knisely BM; Hatim Q; Vaughn-Cooke M
    Pharmaceut Med; 2022 Oct; 36(5):307-317. PubMed ID: 35871475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
    Li X; Lin X; Ren H; Guo J
    J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions.
    Hashiguchi M; Imai S; Uehara K; Maruyama J; Shimizu M; Mochizuki M
    PLoS One; 2015; 10(12):e0144263. PubMed ID: 26641634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
    Cornelius VR; Liu K; Peacock J; Sauzet O
    BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining FDA drug labels for medical conditions.
    Li Q; Deleger L; Lingren T; Zhai H; Kaiser M; Stoutenborough L; Jegga AG; Cohen KB; Solti I
    BMC Med Inform Decis Mak; 2013 Apr; 13():53. PubMed ID: 23617267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADR databases for on-site clinical use: Potentials of summary of products characteristics.
    Eiermann B; Rodriguez D; Cohen P; Gustafsson LL
    Basic Clin Pharmacol Toxicol; 2021 Apr; 128(4):557-567. PubMed ID: 33523597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA.
    Eriksson R; Aagaard L; Jensen LJ; Borisova L; Hørlück D; Brunak S; Hansen EH
    Pharmacol Res Perspect; 2014 Jun; 2(3):e00038. PubMed ID: 25505588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.